CCO Treatment Updates

Novel Approaches in Frontline Multiple Myeloma Therapy: Understanding the Options and Implications for Transplantation

Module

Advances in the Frontline Treatment of Multiple Myeloma

Faculty:

Amitabha Mazumder, MD headshot
  • Amitabha Mazumder, MD

CME CREDIT INFORMATION

Release Date: 06/12/08

Expiration Date: 06/11/09


Physicians: maximum of 1.0 AMA PRA Category 1 Credit(s)

Status: Please log in to view status



Amitabha Mazumder, MD, reviews novel agents and combinations for the frontline clinical management of patients with multiple myeloma.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Explain disease staging in the clinical management of patients with multiple myeloma
  • Discuss the use of bortezomib, both as monotherapy and in combination regimens, in the treatment of multiple myeloma
  • Describe the role of stem cell transplantation in the clinical management of patients with multiple myeloma
  • Articulate differences in treatment options and approaches for elderly vs younger patients with multiple myeloma

Interactive Case Challenges

Clinical Management of a 59-Year-Old Male Patient With Multiple Myeloma and Renal Dysfunction

Faculty:

Jean-Luc Harousseau, MD headshot
  • Jean-Luc Harousseau, MD

CME CREDIT INFORMATION

Release Date: 08/13/08

Expiration Date: 08/12/09


Physicians: maximum of 0.75 AMA PRA Category 1 Credit(s)

Status: Please log in to view status



Join Jean-Luc Harousseau, MD, as he discusses the clinical management of a middle-aged male patient with multiple myeloma and renal dysfunction.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Describe induction treatment options prior to autologous stem cell transplantation
  • Discuss first-line treatment options for patients with renal insufficiency
  • Relate the effective management of bortezomib-induced peripheral neuropathy
  • Summarize options for therapy for multiple myeloma patients following autologous stem cell transplantation

Management of a Transplantation-Eligible 58-Year-Old Male With Newly Diagnosed Multiple Myeloma

Faculty:

William I. Bensinger, MD headshot
  • William I. Bensinger, MD

CME CREDIT INFORMATION

Release Date: 07/02/08

Expiration Date: 07/01/09


Physicians: maximum of 0.75 AMA PRA Category 1 Credit(s)

Status: Please log in to view status



In this Interactive Case Challenge, William I. Bensinger, MD, explores therapeutic options for newly diagnosed myeloma.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Identify optimal induction therapies for patients with newly diagnosed multiple myeloma
  • Describe therapeutic options for a patient with multiple myeloma who has achieved a major response but not a complete response to induction therapy
  • Discuss the implications of achieving a complete response on novel therapy for treatment of newly diagnosed multiple myeloma

Treatment of Newly Diagnosed Multiple Myeloma in a 78-Year-Old Woman

Faculty:

Kenneth Anderson, MD headshot
  • Kenneth Anderson, MD

CME CREDIT INFORMATION

Release Date: 07/25/08

Expiration Date: 07/24/09


Physicians: maximum of 0.75 AMA PRA Category 1 Credit(s)

Status: Please log in to view status



In this Interactive Case Challenge, Kenneth Anderson, MD, reviews current clinical data and explores treatment options for an elderly patient with newly diagnosed multiple myeloma.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Identify optimal frontline treatment options for elderly patients with newly diagnosed multiple myeloma
  • Describe therapeutic options for elderly patients with multiple myeloma who have achieved a complete response to induction therapy
  • Discuss clinical studies relating to the treatment of relapsed multiple myeloma in elderly patients

CCO Slideset

Advances in the Frontline Treatment of Multiple Myeloma


Amitabha Mazumder, MD, reviews the integration of novel agents into the frontline treatment of ASCT-eligible and ASCT-ineligible multiple myeloma patients.


Format: Microsoft PowerPoint (.ppt) | File size: 959 KB


Disclaimer: The materials published on the Clinical Care Options Web site reflect the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the CME provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.

Jointly sponsored by Postgraduate Institute for Medicine and Clinical Care Options, LLC.

Contact Info

This educational program has been supported by

Educational grants support only the CME-certified components of this program.